Sardar, Sumaira
McNair, Christopher M.
Ravindranath, Lakshmi
Chand, Saswati N.
Yuan, Wei
Bogdan, Denisa http://orcid.org/0000-0002-3017-4832
Welti, Jon
Sharp, Adam http://orcid.org/0000-0002-3740-1612
Ryan, Natalie K.
Knudsen, Liam A.
Schiewer, Matthew J.
DeArment, Elise G.
Janas, Thomas
Su, Xiaofeng A.
Butler, Lisa M. http://orcid.org/0000-0003-2698-3220
de Bono, Johann S. http://orcid.org/0000-0002-2034-595X
Frese, Kris
Brooks, Nigel
Pegg, Neil
Knudsen, Karen E.
Shafi, Ayesha A. http://orcid.org/0000-0003-0335-638X
Funding for this research was provided by:
Prostate Cancer Foundation (Young Investigator Award, Challenge Award, Challenge Award)
Wellcome Trust
U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI R01-CA182569)
Article History
Received: 24 June 2024
Revised: 20 August 2024
Accepted: 28 August 2024
First Online: 13 September 2024
Competing interests
: The following are disclosures for authors on this manuscript: Karen E. Knudsen is the CEO of American Cancer Society (ACS). Adam Sharp has received travel support from Sanofi, Roche-Genentech, and Nurix, and speaker honoraria from Astellas Pharma and Merck Sharp & Dohme. He has served as an advisor to DE Shaw Research & CHARM Therapeutics and has been the CI/PI of industry-sponsored clinical trials. No disclosures for the other authors. Neil Pegg, Nigel Brooks, and Kris Frese are employees and shareholders of CellCentric Ltd. Neil Pegg is also a board director and the inventor on CCS1477 patents. Johann S de Bono reports grants from CellCentric during the conduct of the study; grants and personal fees from Daiichi Sankyo, AstraZeneca, Pfizer, Bayer Oncology, MSD, Merck Serono, Harpoon, and Genentech/Roche, personal fees from Eisai and Constellation, and grants from Sun Pharma outside the submitted work; in addition, Johann S. de Bono has a patent for Abiraterone licensed and with royalties paid from Janssen. No other disclosures were reported.
: The use of patient and clinical material was approved by the ethical committees from each of the following institutes: the Sidney Kimmel Cancer Center at Thomas Jefferson University (Pennsylvania, USA), Institute of Cancer Research (ICR – London, United Kingdom), and the University of Adelaide (Adelaide, Australia).